What About Offering a Financial Incentive Directly to Clinical Units to Encourage the Use of Biosimilars? Results of a Two-Year National Experiment in France

BACKGROUND: Regarding the low penetration of biosimilars in the French market, in 2018, the government introduced two mutually exclusive financial incentives to increase biosimilar use. They redirect 20% (general case) or 30% (experimental case) of the price difference between the reference product...

Descripción completa

Detalles Bibliográficos
Autores principales: Tano, Marion, Paubel, Pascal, Ribault, Matthieu, Degrassat-Théas, Albane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228890/
https://www.ncbi.nlm.nih.gov/pubmed/37253898
http://dx.doi.org/10.1007/s40258-023-00812-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228890/
https://www.ncbi.nlm.nih.gov/pubmed/37253898
http://dx.doi.org/10.1007/s40258-023-00812-w

Ejemplares similares